Abstract
Between November 2021 and February 2022, SARS-CoV-2 Delta and Omicron variants co-circulated in the United States, allowing for co-infections and possible recombination events. We sequenced 29,719 positive samples during this period and analyzed the presence and fraction of reads supporting mutations specific to either the Delta or Omicron variant. We identified 18 co-infections, one of which displayed evidence of a low Delta-Omicron recombinant viral population. We also identified two independent cases of infection by a Delta-Omicron recombinant virus, where 100% of the viral RNA came from one clonal recombinant. In the three cases, the 5’-end of the viral genome was from the Delta genome, and the 3’-end from Omicron including the majority of the spike protein gene, though the breakpoints were different. Delta-Omicron recombinant viruses were rare, and there is currently no evidence that Delta-Omicron recombinant viruses are more transmissible between hosts compared to the circulating Omicron lineages.
Competing Interest Statement
A.B., T.B., S.W., A.D.R., D.W., E.K., H.D., T.C., K.T., J.N., J.R., S.C., E.T.C., K.S.B., N.L.W., P.B., S.J., E.S., D.B., J.T.L., M.I., W.L., and S.L. are all employees of Helix.
Funding Statement
This work has been supported by the Centers for Disease Control and funded in part by CDC Contract 75D30121C12730 (Helix). We also thank the NIH RADx initiative, which funded a portion of this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Helix data analyzed and presented here were obtained through IRB protocol WIRB#20203438, which grants a waiver of consent for a limited dataset for the purposes of public health under section 164.512(b) of the Privacy Rule (45 CFR 164.512(b)). All samples were de-identified before receipt by the study investigators.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We added replication results for all co-infection samples and the second recombinant sample. All of these replications were done by re-extracting RNA and resequencing the samples. Replication was possible on 18 of the 20 samples in the first version. To make it clearer, we removed from the main figures the 2 samples with co-infections for whom we could not perform a replication experiment. Previous Figure 1 was moved to Supplementary Figure 1. Analysis results of possible recombination at the 5'end of the spike protein gene in all co-infection samples was added (just a couple of phrases in the text). We added as a reference a recent (after the version 1 of our paper was published) preprint (BioRxiv) from the CDC showing a cluster of 9 Delta-Omicron recombinants in the US, which includes RECOMB1.
Data Availability
All data produced in the present work are contained in the manuscript. SARS-CoV-2 sequences have been uploaded on GISAID. BAM files have been uploaded to SRA Bioproject: PRJNA804575
